Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25792705 | 1.00 | KDM4A (0.44) | KDM4AKDM4CEPHX1KISS1RMAPK1 | |
| SCHEMBL15372053 | 1.00 | KDM4A (0.44) | KDM4AKDM4CEPHX1KISS1RMAPK1 | |
| SCHEMBL22387076 | 0.98 | KDM4A (0.42) | KDM4AKDM4CEPHX1KISS1RMAPK1 | |
| SCHEMBL800590 | 0.91 | KISS1R (0.42) | KDM4AKDM4CEPHX1KISS1RMAPK1 | |
| SCHEMBL19540481 | 0.89 | CASP2 (0.46) | MAPK1MEN1FAAHKMT2A | |
| SCHEMBL9973392 | 0.83 | CES2 (0.48) | MAPK1MEN1FAAHKMT2ACES2 | |
| SCHEMBL18751717 | 0.83 | CES2 (0.48) | MAPK1MEN1FAAHKMT2ACES2 | |
| SCHEMBL9973396 | 0.83 | CES2 (0.48) | MAPK1MEN1FAAHKMT2ACES2 | |
| SCHEMBL26203818 | 0.83 | CES2 (0.48) | MAPK1MEN1FAAHKMT2ACES2 | |
| SCHEMBL27056796 | 0.83 | CES2 (0.48) | MAPK1MEN1FAAHKMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | KDM4A 3459/4885KDM4C 3474/4885EPHX1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.